These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7831073)

  • 21. [Methylene blue: an effective therapeutic alternative for priapism induced by intracavernous injection of vasoactive agents].
    Martínez Portillo FJ; Fernández Arancibia MI; Bach S; Alken P; Jünemann KP
    Arch Esp Urol; 2002 Apr; 55(3):303-8. PubMed ID: 12068762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of prolonged or priapistic erections following intracavernosal papaverine therapy.
    Padma-Nathan H; Goldstein I; Krane RJ
    Semin Urol; 1986 Nov; 4(4):236-8. PubMed ID: 3797893
    [No Abstract]   [Full Text] [Related]  

  • 23. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
    Chen J; Godschalk M; Katz PG; Mulligan T
    J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Priapism induced by intracavernous injection].
    Morales Concepción JC
    Arch Esp Urol; 1992 Oct; 45(8):793-5. PubMed ID: 1466580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intracavernous injection of papaverine hydrochloride for impotence in patients with spinal cord injury].
    Momose H; Natsume O; Yamamoto M; Suemori T; Yamada K
    Hinyokika Kiyo; 1987 Jul; 33(7):1065-9. PubMed ID: 3687629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence and management of priapism in Western Australia: a 16 year audit.
    Earle CM; Stuckey BG; Ching HL; Wisniewski ZS
    Int J Impot Res; 2003 Aug; 15(4):272-6. PubMed ID: 12934055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injection therapy for impotence.
    Kursh ED; Bodner DR; Resnick MI; Althof SE; Turner L; Risen C; Levine SB
    Urol Clin North Am; 1988 Nov; 15(4):625-9. PubMed ID: 3055615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Priapism as a complication following diagnostic papaverine test].
    Darewicz J; Galek L
    Z Urol Nephrol; 1989 Jun; 82(6):317-9. PubMed ID: 2763728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine.
    Viswaroop B; B A; Gopalakrishnan G
    Natl Med J India; 2005; 18(6):299-301. PubMed ID: 16483029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biweekly intracavernous administration of papaverine for erectile dysfunction.
    Mooradian AD; Morley JE; Kaiser FE; Davis SS; Viosca SP; Korenman SC
    West J Med; 1989 Nov; 151(5):515-7. PubMed ID: 2603417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
    Hirsch IH; Smith RL; Chancellor MB; Bagley DH; Carsello J; Staas WE
    Paraplegia; 1994 Oct; 32(10):661-4. PubMed ID: 7831071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Priapism following intracavernous injection of vasoactive substances as a urologic emergency].
    Papadopoulos I; Weichert-Jacobsen K; Wand H
    Z Urol Nephrol; 1990 May; 83(5):233-7. PubMed ID: 2392883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic erection: time-dependent changes in the corporal environment.
    Broderick GA; Harkaway R
    Int J Impot Res; 1994 Mar; 6(1):9-16. PubMed ID: 8019618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of pharmacological priapism with phenylephrine.
    Dittrich A; Albrecht K; Bar-Moshe O; Vandendris M
    J Urol; 1991 Aug; 146(2):323-4. PubMed ID: 1856926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of phenylephrine and terbutaline on ischemic priapism: a retrospective review.
    Martin C; Cocchio C
    Am J Emerg Med; 2016 Feb; 34(2):222-4. PubMed ID: 26597497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for papaverine-induced priapism.
    Lomas GM; Jarow JP
    J Urol; 1992 May; 147(5):1280-1. PubMed ID: 1569668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.